Skip to main content

Table 2 MS disease activity over the 2-year study period

From: Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate

Patients, n (%)

LA

CWE

EE

(n = 251)

(n = 246)

(n = 153)

Stable MS (Stage 1)

37 (14.7)

47 (19.1)

22 (14.4)

Rare exacerbations (≤1 per year, Stage 2a)

70 (27.9)

107 (43.5)

101 (66.0)

Slow progression (≤0.5 EDSS points per year, Stage 2b)

48 (19.1)

35 (14.2)

6 (3.9)

Frequent exacerbations (>1 per year, Stage 3a)

80 (31.9)

43 (17.5)

21 (13.7)

Fast progression (>0.5 EDSS points per year, Stage 3b)

11 (4.4)

3 (1.2)

1 (0.7)

Not classified/not available

5 (2.0)

11 (4.5)

2 (1.3)